Early-line immunotherapy in multiple myeloma: reshaping the treatment paradigm

嵌合抗原受体 医学 免疫疗法 免疫学 抗原 免疫系统 临床试验 肿瘤科 疾病 微小残留病 移植 抗体 骨髓 人类白细胞抗原 细胞疗法 双特异性抗体 T细胞 主要组织相容性复合体 生物信息学 托珠单抗 多发性骨髓瘤 免疫耐受 干细胞 疾病负担 生物反应调节剂 免疫抑制
作者
Rida Darji,Curtis Marcoux,Mahmoud Gaballa,Aimaz Afrough,Meera Mohan,Krina K. Patel,Oren Pasvolsky
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:17: 1981988-1981988
标识
DOI:10.3389/fimmu.2026.1981988
摘要

Multiple myeloma (MM) has traditionally been considered to be incurable, despite increasingly effective induction, transplantation, and maintenance strategies. Chimeric antigen receptor (CAR) T-cell therapies and T-cell-redirecting bispecific antibodies have produced deep and durable responses in heavily pretreated disease and are now moving into earlier lines of therapy. The biologic rationale for earlier use includes the potential for greater T-cell fitness, a more permissive bone marrow immune microenvironment, a lower burden of treatment-resistant disease, and the need to deliver effective therapy before attrition prevents patients from receiving effective treatments. Randomized trials have established the superiority of B-cell maturation antigen (BCMA)-directed CAR T-cell therapy and BCMA- or G protein-coupled receptor class C group 5 member D (GPRC5D)-directed bispecific regimens over conventional therapies in early relapse. In contrast, frontline use remains investigational, with predominantly small, nonrandomized studies and limited follow-up. Ongoing studies are evaluating these approaches as induction, consolidation, maintenance, and measurable residual disease (MRD)-directed therapy, as well as potential alternatives to autologous stem cell transplantation. However, moving T-cell-redirecting immunotherapy earlier introduces important biological and clinical challenges, including sustained immune and antigen engagement, antigen escape and distinct toxicities. Optimal sequencing across targets and treatment modalities, as well as the optimal duration of therapy, remain areas of active investigation. The high efficacy of modern anti-CD38-based quadruplets and transplantation also establishes a demanding benchmark against which early-line immunotherapy must be assessed. In this review, we examine the immunological and clinical rationale for earlier treatment, summarize emerging evidence for CAR T-cell therapies and bispecific antibodies in early-relapsed and newly diagnosed myeloma, and discuss their evolving relationship with autologous transplantation. We further highlight the need for prospective sequencing studies, sustained MRD endpoints and fixed-duration/response-adapted strategies to determine whether earlier immunotherapy can provide durable disease control while reducing cumulative treatment exposure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
优秀钢铁侠完成签到,获得积分10
1秒前
1秒前
1秒前
Mishaoc完成签到,获得积分10
1秒前
Liah完成签到,获得积分10
1秒前
2秒前
2秒前
yyyyy完成签到 ,获得积分10
2秒前
满意的苑博完成签到,获得积分20
2秒前
FashionBoy的应助被wjswift采纳,获得10
2秒前
曾经的哲瀚完成签到,获得积分10
2秒前
务实寄松发布了新的文献求助10
2秒前
2秒前
风吹麦浪发布了新的文献求助10
2秒前
风吹麦浪发布了新的文献求助30
2秒前
3秒前
科研通AI6.3的应助被zs采纳,获得10
3秒前
gujianhua发布了新的文献求助10
3秒前
Maestro_S的应助被anbude采纳,获得10
3秒前
风吹麦浪发布了新的文献求助10
3秒前
maomao发布了新的文献求助10
3秒前
3秒前
3秒前
单纯的石头完成签到 ,获得积分10
3秒前
NexusExplorer的应助被Zengjx采纳,获得10
4秒前
知行者完成签到,获得积分10
4秒前
深情安青的应助被繁荣的傲南采纳,获得10
4秒前
风吹麦浪的应助被迪迪张采纳,获得10
4秒前
4秒前
蛋蛋完成签到,获得积分10
4秒前
嘟嘟咪发布了新的文献求助10
4秒前
4秒前
5秒前
HMO_eee完成签到,获得积分10
5秒前
别拿暗恋当饭吃完成签到 ,获得积分10
5秒前
5秒前
潇洒的如风完成签到,获得积分10
5秒前
从容水壶发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181014
求助须知:如何正确求助?哪些是违规求助? 9571039
关于积分的说明 21816042
捐赠科研通 7777369
什么是DOI,文献DOI怎么找? 3433378
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479385